The therapy relies on human retinal pigment epithelial cells engineered to secrete leptin, a hormone typically associated with appetite regulation. These cells are housed in microscopic alginate spheres that shield them from immune system attacks while allowing proteins to diffuse into the bloodstream. Once injected subcutaneously, the cells provide a temporary surge of the hormone before naturally losing viability, ensuring the intervention remains reversible.
In preclinical trials, the results were consistent across species. Mice adapted to a four-hour schedule delay 50% faster than untreated controls. When tested in cynomolgus macaques, whose sleep patterns closely mirror humans, the treatment reduced entrainment time following six-hour shifts by approximately one day. Crucially, the researchers noted no adverse effects on sleep architecture or toxicity levels, with subjects maintaining healthy REM and non-REM cycles throughout the recovery period.




Comments (0)
No comments yet. Be the first!